Pasithea Therapeutics
KTTA
7 hedge funds and large institutions have $243K invested in Pasithea Therapeutics in 2024 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 0 closing their positions.
398% more capital invested
Capital invested by funds: $48.9K → $243K (+$194K)
17% more funds holding
Funds holding: 6 → 7 (+1)
5.2% more ownership
Funds ownership: 0.87% → 6.08% (+5.2%)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$216K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$22.3K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$4.55K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$1.77K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$35 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $192K | +$216K | +61,000 | New |
|
|
2
UBS Group
Zurich,
Switzerland
| $40.5K | +$22.3K | +6,301 | +96% |
|
|
TRCT
3
Tower Research Capital (TRC)
New York
| $5.94K | +$4.55K | +1,285 | +214% |
|
|
4
Morgan Stanley
New York
| $3.15K | -$1.77K | -500 | -33% |
|
5
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | – | – | – |
|
6
JP Morgan Chase
New York
| $473 | – | – | – |
|
|
7
Bank of America
Charlotte,
North Carolina
| $25 | -$35 | -10 | -56% |
|
KTTA Hedge Fund Activity: Q4 2024 in Review
7 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Pasithea Therapeutics (KTTA) for Q4 2024, worth a combined $243K — up 398% from $48.9K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new KTTA positions and 0 closed out — a net gain of 1 holder — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $216K. The largest seller was Morgan Stanley, cutting an estimated $1.77K.
- 7 institutional investors held Pasithea Therapeutics (KTTA) as of Q4 2024, up from 6 in Q3 2024.
- Funds reported $243K of Pasithea Therapeutics stock for Q4 2024, up 398% quarter-over-quarter.
- 1 fund opened new Pasithea Therapeutics positions in Q4 2024 and 0 closed out, a net change of +1 holder.
- The largest Pasithea Therapeutics buyer in Q4 2024 was Armistice Capital, an estimated $216K added.
- The largest Pasithea Therapeutics seller in Q4 2024 was Morgan Stanley, an estimated $1.77K sold.
Based on aggregated 13F filings for Q4 2024.